Exact Sciences (EXAS) Expected to Announce Quarterly Earnings on Wednesday

Exact Sciences (NASDAQ:EXAS) is expected to be announcing its earnings results after the market closes on Wednesday, February 19th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $701.45 million for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Exact Sciences Trading Down 2.5 %

Shares of Exact Sciences stock opened at $49.31 on Tuesday. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. Exact Sciences has a 12-month low of $40.62 and a 12-month high of $79.62. The firm has a market capitalization of $9.13 billion, a price-to-earnings ratio of -42.14 and a beta of 1.24. The firm’s 50 day simple moving average is $55.90 and its two-hundred day simple moving average is $60.23.

Wall Street Analysts Forecast Growth

EXAS has been the topic of a number of recent analyst reports. William Blair reissued an “outperform” rating on shares of Exact Sciences in a report on Monday, January 13th. Craig Hallum dropped their target price on shares of Exact Sciences from $82.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. BTIG Research raised their price target on shares of Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Bank of America reduced their price target on shares of Exact Sciences from $75.00 to $72.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Finally, Stifel Nicolaus dropped their price objective on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, Exact Sciences presently has an average rating of “Moderate Buy” and an average target price of $72.76.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.